Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis.
Biomarkers
Chemokines
Extracellular matrix
Idiopathic pulmonary fibrosis
Mast cells
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
24 Oct 2021
24 Oct 2021
Historique:
received:
02
06
2021
accepted:
09
10
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a significant unmet medical need. Development of transformational therapies for IPF is challenging in part to due to lack of robust predictive biomarkers of prognosis and treatment response. Importantly, circulating biomarkers of IPF are limited and none are in clinical use. We previously reported dysregulated pathways and new disease biomarkers in advanced IPF through RNA sequencing of lung tissues from a cohort of transplant-stage IPF patients (n = 36) in comparison to normal healthy donors (n = 19) and patients with acute lung injury (n = 11). Here we performed proteomic profiling of matching plasma samples from these cohorts through the Somascan-1300 SomaLogics platform. Comparative analyses of lung transcriptomic and plasma proteomic signatures identified a set of 34 differentially expressed analytes (fold change (FC) ≥ ± 1.5, false discovery ratio (FDR) ≤ 0.1) in IPF samples compared to healthy controls. IPF samples showed strong enrichment of chemotaxis, tumor infiltration and mast cell migration pathways and downregulated extracellular matrix (ECM) degradation. Mucosal (CCL25 and CCL28) and Th2 (CCL17 and CCL22) chemokines were markedly upregulated in IPF and highly correlated within the subjects. The mast cell maturation chemokine, CXCL12, was also upregulated in IPF plasma (fold change 1.92, FDR 0.006) and significantly correlated (Pearson r = - 0.38, p = 0.022) to lung function (%predicted FVC), with a concomitant increase in the mast cell Tryptase, TPSB2. Markers of collagen III and VI degradation (C3M and C6M) were significantly downregulated (C3M p < 0.001 and C6M p < 0.0001 IPF vs control) and correlated, Pearson r = 0.77) in advanced IPF consistent with altered ECM homeostasis. Our study identifies a panel of tissue and circulating biomarkers with clinical utility in IPF that can be validated in future studies across larger cohorts.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a significant unmet medical need. Development of transformational therapies for IPF is challenging in part to due to lack of robust predictive biomarkers of prognosis and treatment response. Importantly, circulating biomarkers of IPF are limited and none are in clinical use.
METHODS
METHODS
We previously reported dysregulated pathways and new disease biomarkers in advanced IPF through RNA sequencing of lung tissues from a cohort of transplant-stage IPF patients (n = 36) in comparison to normal healthy donors (n = 19) and patients with acute lung injury (n = 11). Here we performed proteomic profiling of matching plasma samples from these cohorts through the Somascan-1300 SomaLogics platform.
RESULTS
RESULTS
Comparative analyses of lung transcriptomic and plasma proteomic signatures identified a set of 34 differentially expressed analytes (fold change (FC) ≥ ± 1.5, false discovery ratio (FDR) ≤ 0.1) in IPF samples compared to healthy controls. IPF samples showed strong enrichment of chemotaxis, tumor infiltration and mast cell migration pathways and downregulated extracellular matrix (ECM) degradation. Mucosal (CCL25 and CCL28) and Th2 (CCL17 and CCL22) chemokines were markedly upregulated in IPF and highly correlated within the subjects. The mast cell maturation chemokine, CXCL12, was also upregulated in IPF plasma (fold change 1.92, FDR 0.006) and significantly correlated (Pearson r = - 0.38, p = 0.022) to lung function (%predicted FVC), with a concomitant increase in the mast cell Tryptase, TPSB2. Markers of collagen III and VI degradation (C3M and C6M) were significantly downregulated (C3M p < 0.001 and C6M p < 0.0001 IPF vs control) and correlated, Pearson r = 0.77) in advanced IPF consistent with altered ECM homeostasis.
CONCLUSIONS
CONCLUSIONS
Our study identifies a panel of tissue and circulating biomarkers with clinical utility in IPF that can be validated in future studies across larger cohorts.
Identifiants
pubmed: 34689792
doi: 10.1186/s12931-021-01860-3
pii: 10.1186/s12931-021-01860-3
pmc: PMC8543878
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL145408
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL152970
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
PLoS One. 2008 May 14;3(5):e2142
pubmed: 18478089
Clin Exp Allergy. 2003 May;33(5):705-13
pubmed: 12752602
Science. 2004 Sep 17;305(5691):1776-9
pubmed: 15375268
Respir Res. 2011 Oct 20;12:139
pubmed: 22014187
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135312
Am J Respir Crit Care Med. 2016 Oct 15;194(8):948-960
pubmed: 27104832
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
Semin Immunopathol. 2019 May;41(3):339-348
pubmed: 30968186
Am J Respir Crit Care Med. 2021 Mar 15;203(6):707-717
pubmed: 32991815
Clin Biochem. 2010 Jul;43(10-11):899-904
pubmed: 20380828
Respir Res. 2019 Sep 6;20(1):205
pubmed: 31492155
Lancet Respir Med. 2019 Mar;7(3):271-282
pubmed: 30738856
PLoS One. 2011;6(9):e24753
pubmed: 21935455
Front Med (Lausanne). 2020 Dec 16;7:611728
pubmed: 33392232
Expert Rev Respir Med. 2019 Jan;13(1):39-51
pubmed: 30526140
Respir Res. 2020 Jun 30;21(1):165
pubmed: 32605572
Front Immunol. 2019 May 29;10:821
pubmed: 31191511
J Immunol. 2011 Feb 1;186(3):1861-9
pubmed: 21187436
Hum Pathol. 2021 Jan;107:58-68
pubmed: 33161029
Am J Respir Cell Mol Biol. 2021 Oct;65(4):430-441
pubmed: 34038697
PLoS One. 2016 Mar 21;11(3):e0151765
pubmed: 26998906
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Dis Primers. 2017 Oct 20;3:17074
pubmed: 29052582
ERJ Open Res. 2019 Aug 12;5(3):
pubmed: 31423451
Am J Pathol. 2007 Apr;170(4):1152-64
pubmed: 17392156
Lung. 2018 Oct;196(5):543-552
pubmed: 30066212
Expert Opin Pharmacother. 2021 Feb;22(2):191-204
pubmed: 32993388
Front Pharmacol. 2014 Jan 23;5:2
pubmed: 24478703
Adv Exp Med Biol. 2013;735:283-300
pubmed: 23402035
Respir Res. 2020 Aug 26;21(1):221
pubmed: 32843095
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Respirology. 2020 Jul;25(7):674-675
pubmed: 31849128
Sci Adv. 2020 Jul 08;6(28):eaba1983
pubmed: 32832599
Mol Omics. 2021 Feb 22;17(1):43-58
pubmed: 33073811
Thorax. 2019 Mar;74(3):309-312
pubmed: 30244194
Lancet Respir Med. 2015 Jun;3(6):462-72
pubmed: 25770676
Respir Res. 2009 Aug 29;10:80
pubmed: 19715610
Respir Res. 2019 Jan 11;20(1):7
pubmed: 30634961
Respir Res. 2019 Jul 12;20(1):148
pubmed: 31299951
Thorax. 2019 May;74(5):455-465
pubmed: 30808717
Thorax. 2020 Sep;75(9):754-763
pubmed: 32709610
Cell Signal. 2020 Feb;66:109482
pubmed: 31760172
Respir Res. 2019 Oct 22;20(1):227
pubmed: 31640794
Exp Ther Med. 2020 Mar;19(3):1844-1854
pubmed: 32104240
Cancer Biol Ther. 2018;19(10):904-912
pubmed: 30067436
Am J Med Sci. 2019 May;357(5):370-373
pubmed: 31010462
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536
pubmed: 30554520
PLoS One. 2020 Mar 11;15(3):e0229445
pubmed: 32160239